Side-by-side comparison of AI visibility scores, market position, and capabilities
Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.
Nasdaq-listed (PRME). $191M cash runway into 2027. IND for Wilson's Disease H1 2026. AATD IND mid-2026. $3.5B+ BMS collaboration. CGD Phase 1 showing rapid function restoration after single infusion.
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable of making all 12 possible base-pair changes, small insertions, and deletions in DNA without double-strand breaks. The company has $191 million in cash runway into 2027, INDs planned for Wilson's Disease and Alpha-1 antitrypsin deficiency (AATD) in 2026, and a $55 million upfront collaboration with Bristol Myers Squibb worth up to $3.5 billion in milestones.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.